Viewing nowEmpagliflozin 25 mg Tablet (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Medica Korea Co., Ltd.

MFDS item code 202102080 · Approved 2021.03.05 · Insurance code 646005270
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug is used in conjunction with diet and exercise to help control blood sugar in adults with type 2 diabetes. It can be administered alone, but in cases where blood sugar control is difficult, it is used in combination with metformin, pioglitazone, sulfonylureas, insulin, or the DPP-4 inhibitor linagliptin. It should be used cautiously in patients with type 2 diabetes who have cardiovascular disease, according to professional guidelines. This drug effectively improves blood sugar levels and is used in diabetes treatment.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited
This drug should not be used in patients with allergies to the active ingredient or other components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This drug is not used in patients with severely impaired renal function, end-stage renal disease, or those undergoing dialysis. Since this drug contains lactose, it should not be given to patients with lactose intolerance or related genetic disorders. Patients with mildly impaired renal function may require dosage adjustments, and if function worsens, administration should be discontinued. This drug is not expected to be effective in patients with end-stage renal disease or those undergoing dialysis. Caution should be exercised in patients with mild to moderate heart failure, and it is not recommended for patients with severe heart failure. There may be a risk of hypoglycemia when used in conjunction with insulin or sulfonylureas, necessitating dosage adjustments. When taking this drug, it is important to be aware of potential side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, decreased fluid volume, liver dysfunction, etc. The risk of hypoglycemia may be increased, especially when used alongside insulin or sulfonylureas. Moreover, serious adverse reactions such as ketoacidosis or perineal necrosis have been reported; if symptoms appear, immediate medical consultation is necessary. Since this drug carries a risk of ketoacidosis, any metabolic acidosis symptoms should prompt immediate testing and treatment. Elderly patients or those with low blood pressure should be cautious about dehydration and hypotension. Rapid treatment is advised for any signs of urinary and genital infections. When used with other diuretics, there may be an increased risk of dehydration and hypotension. There is a potential for hypoglycemia when combined with insulin secretagogues, requiring dosage adjustments. The 1,5-AG test for evaluating blood sugar control is unreliable, and alternative methods should be used. Use of this drug during pregnancy is not recommended, and administration should be discontinued upon confirmation of pregnancy. During lactation, as this drug may be secreted in breast milk and affect the newborn, breastfeeding should be stopped. Safety and efficacy in children under 18 years have not been established. No specific toxicity has been reported in cases of overdose, but appropriate treatment based on clinical conditions is necessary. This drug should be stored out of reach of children, and transferring it to another container is not recommended. Caution is necessary when driving or operating machinery due to the risk of hypoglycemia, especially when taken alongside insulin or sulfonylureas. Diabetic patients should pay attention to regular foot care and infection prevention, and if any pain or abnormal symptoms around the perineum occur, they should immediately inform medical personnel.
Not everyone experiences these, and they can vary from person to person.
This drug must be stored in a tightly closed container to protect it from air and moisture. It is also important to store it at room temperature between 1 and 30 degrees Celsius to maintain the drug's efficacy.
Pale yellow, bi-convex, oval-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Medica Korea Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.